Benjamin Daquioag.
Phone number 713-526-9821 ext217


A phase III, randomised, double-blind and placebo-controlled study of once daily BI 201335 240  mg for 12 and 24 weeks in combination with pegylated interferon-α and ribavirin in patients with genotype 1 chronic hepatitis C infection who failed a prior PegIFN/RBV treatment

Copyright © 2024. Cure C Consortium